Amikacin, Peak, Serum
Amikacin is an aminoglycoside antibiotic used to treat gram negative bacterial and some mycobacterial infections. It works by binding to the bacterial 30s ribosomal subunit and inhibiting protein synthesis. Amikacin has a narrow therapeutic index and overdosage can cause both auditory and renal toxicity. There can be wide variation between the administered dose and the serum level due to differences in the physiological, pathological or metabolic state of the patient. In particular, in patients with renal impairment the dose should be adjusted based on the patient’s creatinine clearance.
In order to determine the effective dose and prevent toxicity, therapeutic drug monitoring (TDM) is typically performed. For amikacin, peak levels (drawn 30 minutes after IV and 60 minutes after IM dose) should be 20-30 ug/mL and trough levels (collected 30 minutes before the next dose) should be < 8.0 ug/mL except in cases of life-threatening infection. Efficacy is related to the peak levels and toxicity is related to the trough levels. Amikacin interacts with several other drugs including penicillin, cephalosporins, NSAIDs, quinidine, tetracycline, chloramphenicol, clindamycin and diuretics.
- To determine the effective dose of drug a patient should take to reach a therapeutic range in serum
- To adjust the drug dose based on patient’s response
- To avoid toxic effect of drug having narrow therapeutic window
- The therapeutic response may not be seen at a serum concentration <20 µg/mL.
- Toxic effects may be seen at trough serum concentration ≥ 10 µg/mL.
Trough Levels: 4-8 µg/mL Peak Levels: 20-30 µg/mL
Serum (SST tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 1 month
- J Antimicrob Chemother.2016;71 (10). 2754-2759. [PMID: 27494904]
- J Basic Clin Pharm. 2016; 7(3): 65–69. [PMID: 27330257]
- J Antimicrob Chemother. 2009;63(2):246-51. [PMID: 19022778]
- Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):157-166. [PMID: 27623706]